OTCMKTS:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis $6.50 +1.10 (+20.37%) As of 10/23/2026 03:18 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Interpace Biosciences Stock (OTCMKTS:IDXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Interpace Biosciences alerts:Sign Up Key Stats Today's Range$5.80▼$6.5050-Day Range$5.00▼$8.5052-Week Range$5.00▼$6.50Volume2,753 shsAverage Volume1,358 shsMarket Capitalization$36.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Interpace Biosciences, Inc. is a molecular diagnostics company focused on helping physicians evaluate cancer risk and make more informed treatment decisions. The company develops and commercializes molecular tests that analyze genetic and other biological information from patient samples. Its diagnostic offerings have included ThyGeNEXT and ThyraMIR, which are designed to help assess indeterminate thyroid nodules, and PancraGEN, a test used in evaluating pancreatic cysts. Interpace has also developed testing and related services for gastrointestinal conditions, including Barrett’s esophagus, as well as biomarker and companion-diagnostic programs through its pharmaceutical services activities. Interpace’s products are intended for use by healthcare providers, hospitals, laboratories and pharmaceutical companies, primarily in the United States. The company was formerly known as Interpace Diagnostics Group, Inc. and adopted the Interpace Biosciences name as it expanded its focus beyond diagnostic testing into broader precision-medicine and biopharmaceutical services.AI Generated. May Contain Errors. Read More Interpace Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreIDXG MarketRank™: 0.332219251335 of 5 starsInterpace Biosciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Interpace Biosciences. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioInterpace Biosciences has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Interpace Biosciences has been sold short.Short Interest Ratio / Days to CoverInterpace Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterpace Biosciences does not currently pay a dividend.Dividend GrowthInterpace Biosciences does not have a long track record of dividend growth. News and Social Media0.9 / 5News Sentiment-0.61 News SentimentInterpace Biosciences has a news sentiment score of -0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Interpace Biosciences this week, compared to 2 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Interpace Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders0.93% of the stock of Interpace Biosciences is held by insiders.Percentage Held by Institutions5.73% of the stock of Interpace Biosciences is held by institutions.Read more about Interpace Biosciences' insider trading history. Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXG Stock News HeadlinesBorsa Istanbul Imposes Temporary Circuit Breaker on TNZTP.EOctober 23 at 5:30 AM | tipranks.comPDI Gold Adds Auditor Appointment Resolution to November AGM AgendaOctober 23 at 4:11 AM | tipranks.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)PDI Gold expands ASX-quoted share base with new ordinary securitiesOctober 23 at 4:11 AM | tipranks.comPDI Gold sets November 2026 date for dual-access annual general meetingOctober 20, 2026 | tipranks.comPDI Gold moves to electronic communications for November AGMOctober 20, 2026 | tipranks.comCircuit Breaker Halts Continuous Trading in TAPDI Oksijen’s TNZTP SharesOctober 16, 2026 | tipranks.comA PDI Cut Is Priced In AlreadyOctober 15, 2026 | seekingalpha.comSee More Headlines IDXG Stock Analysis - Frequently Asked Questions How have IDXG shares performed this year? Interpace Biosciences' stock was trading at $6.1510 at the start of the year. Since then, IDXG stock has increased by 5.7% and is now trading at $6.50. How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (OTCMKTS:IDXG) issued its quarterly earnings results on Monday, August, 10th. The business services provider reported $0.05 earnings per share (EPS) for the quarter. The business services provider earned $9.13 million during the quarter. Interpace Biosciences had a trailing twelve-month return on equity of 145.40% and a net margin of 67.64%. When did Interpace Biosciences' stock split? Shares of Interpace Biosciences reverse split on Thursday, August 27th 2026.The 1-5 reverse split was announced on Thursday, August 27th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Interpace Biosciences? Shares of IDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), Block (XYZ), Johnson & Johnson (JNJ) and NVIDIA (NVDA). Company Calendar Last Earnings8/10/2026Today10/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolOTCMKTS:IDXG CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees102Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.40 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$24.58 million Net Margins67.64% Pretax Margin11.06% Return on Equity145.40% Return on Assets87.36% Debt Debt-to-Equity RatioN/A Current Ratio2.22 Quick Ratio2.22 Sales & Book Value Annual Sales$38.73 million Price / Sales0.93 Cash Flow$36.11 per share Price / Cash Flow0.18 Book Value$25.25 per share Price / Book0.26Miscellaneous Outstanding Shares5,540,000Free Float5,490,000Market Cap$36.01 million OptionableNot Optionable Beta0.63 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (OTCMKTS:IDXG) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
